Released on = May 19, 2006, 9:30 am

Press Release Author = Visiongain

Industry =

Press Release Summary = The generic pharmaceutical market is thriving and will
continue to grow, according to a new report by visiongain.

Press Release Body = San Francisco, CA and London, UK; 19 May 2006: The generic
pharmaceutical market is thriving and will continue to grow, according to a new
report by visiongain: "The World Generics Market, 2006-2011". In 2005 the global
market was worth $45billion, an increase of almost 15% on the year before.
Visiongain forecasts similar growth over the next five years, as many of the most
successful blockbuster drugs of recent years will lose patent protection in key
markets.

By 2009 at least $80bn worth of revenues from the current leading 200 drugs will be
exposed to high levels of generic competition due to patent loss. The generic
pharmaceutical industry is extremely well placed to take advantage of this,
especially the large global companies such as Teva, Sandoz and Merck KgaA. The lack
of any successful 3rd generation drugs in successful markets such antidepressants
and cholesterol treatments will further add to the woes of the branded
pharmaceutical market.

"The current business model pharmaceutical requires the continued development of
novel improved treatments", says Dr Tom Newton pharmaceutical market analyst at
visiongain. "When this doesn't happen then the major beneficiaries are the generics
companies".

Another major contributory factor to the growth of the generic market is that there
are increasing cost pressures on governments and healthcare providers around the
world. Encouraging the use of generic medicines is an obvious way to cut costs and
even countries that have not had strong generics markets in the past have started to
introduce pro-generic legislation

The future will also contain significant challenges for the generic industry. The
most pressing issue for the market is the lack of any clear guidelines for generic
biotech drugs (biogenerics) in the US. The increased use of authorised generic
strategies by big Pharma is also causing concerns amongst generic companies


ENDS
Notes for editors: To receive your complimentary overview of - The World Generics
Market 2006-2011 - Please send an email to Sara Peerun sara.peerun@visiongain.com,
telephone Sara on +44 (0) 20 8767 6711 or see www.visiongainintelligence.com. Please
include your full name, title of publication, contact telephone number, email, and
details of where you saw this release. Upon receipt of this information, an overview
will be emailed to you.

Background:
Visiongain is one of the fastest growing and most innovative independent media
companies in Europe today. Based in London, UK, visiongain produce a host of
business-2-business conferences, newsletters, management reports and E-Zines
focusing on the Financial markets, the Pharmaceutical, Telecoms industries and the
Defence sector.

For information on visiongain, please visit www.visiongainintelligence.com


Web Site = http://www.visiongain.com

Contact Details = 40 Tooting High Street
London SW17 0GR